ImmunityBio (IBRX) Invested Capital (2016 - 2025)
Historic Invested Capital for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$524.3 million.
- ImmunityBio's Invested Capital fell 52677.87% to -$524.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$524.3 million, marking a year-over-year decrease of 52677.87%. This contributed to the annual value of $202.4 million for FY2024, which is 211679.95% up from last year.
- Per ImmunityBio's latest filing, its Invested Capital stood at -$524.3 million for Q3 2025, which was down 52677.87% from -$570.7 million recorded in Q2 2025.
- In the past 5 years, ImmunityBio's Invested Capital registered a high of $202.4 million during Q4 2024, and its lowest value of -$697.4 million during Q2 2024.
- Its 5-year average for Invested Capital is -$295.4 million, with a median of -$337.6 million in 2022.
- As far as peak fluctuations go, ImmunityBio's Invested Capital plummeted by 95430.24% in 2021, and later soared by 211679.95% in 2024.
- Over the past 5 years, ImmunityBio's Invested Capital (Quarter) stood at -$243.9 million in 2021, then skyrocketed by 92.65% to -$17.9 million in 2022, then soared by 43.99% to -$10.0 million in 2023, then soared by 2116.8% to $202.4 million in 2024, then crashed by 359.04% to -$524.3 million in 2025.
- Its last three reported values are -$524.3 million in Q3 2025, -$570.7 million for Q2 2025, and $84.6 million during Q1 2025.